<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Velazquez, Eric J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">No Mortality Benefit from CABG When Added to Optimal Medical Therapy in Patients with CAD and LV Dysfunction: Results from the STICH Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Results from the Surgical Treatment of Ischemic Heart Failure STICH trial [NCT00023595] showed no mortality benefit from coronary artery bypass grafting in addition to intensive guideline-based medical therapy compared with medical therapy alone.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>